Trial Profile
PD-1 Blockade With Pembrolizumab in Relapsed or Refractory Natural Killer/T Cell Lymphoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2019
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications T-cell lymphoma
- Focus Therapeutic Use
- 13 Apr 2017 New trial record